As published in the New England Journal of Medicine (NEJM), a targeted therapy for children with high-risk Hodgkin’s lymphoma (HL) was shown to significantly reduce relapse rates – by 10% – when tested in a large multicenter clinical trial conducted by the Children’s Oncology Group (COG) and led by pediatric oncologists at Winship Cancer Institute of Emory University, Children’s Healthcare of Atlanta and Roswell Park Comprehensive Cancer Center.
The study combined the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen. "We are optimistic that this trial will set the stage for FDA approval of this targeted antibody drug conjugate for children and adolescents," says Sharon Castellino, MD, MSc, study first author and Winship research member.
